Genmab — Remuneration Information 2017

Mar 29, 2017

Company Announcement

Copenhagen, Denmark; March 29, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN)
announced today that at a board meeting the board decided to grant 5,042
restricted stock units to the two new board members and to the new member of
management of the Company and 8,400 warrants to the new member of management of
the Company.

Each restricted stock unit is awarded cost-free and provides the owner with a
right and obligation to receive one share in Genmab A/S of nominally DKK 1. The
fair value of each restricted stock unit is equal to the closing market price
on the date of grant of one Genmab A/S share, DKK 1,427.

The restricted stock units will vest on the first banking day of the month
following a period of three years from the date of grant. Furthermore, the
restricted stock units are subject to vesting conditions set out in the
restricted stock unit program adopted by the board of directors in accordance
with the general guidelines for incentive-based remuneration adopted by the
shareholders at the annual general meeting. Information concerning Genmab’s
restricted stock unit program can be found on www.genmab.com under Investors >
Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,427. Each warrant is awarded
cost-free and entitles the owner to subscribe one share of nominally DKK 1
subject to payment of the exercise price. By application of the Black-Scholes
formula, the fair value of each warrant can be calculated as DKK 473.44.

The warrants vest three years after the grant date, and all warrants expire at
the seventh anniversary of the grant date. The new warrants were granted
pursuant to the warrant plan adopted by the board on March 28, 2017.
Information concerning Genmab’s warrant schemes can be found on www.genmab.com
under Investors > Stock information > Warrants.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
DARZALEX® (daratumumab) for the treatment of certain multiple myeloma
indications, and Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications. Daratumumab is in clinical development for
additional multiple myeloma indications, other blood cancers, and solid tumors.
A subcutaneous formulation of ofatumumab is in development for relapsing
multiple sclerosis. Genmab also has a broad clinical and pre-clinical product
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody® platform which creates effector
function enhanced antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 12
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark